Search
Three outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.
Five The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.
A year after launching the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities, The Kids Research Institute Australia has released a new resource as part of the guideline.
Aboriginal community members throughout the Kimberley will take a lead role in driving healthy skin messages within their own communities thanks to a major funding boost to The Kids Research Institute Australia’s SToP Trial.
Our aim is for all kids to have healthy skin. We work with communities to reduce the burden of Strep A skin sores and sore throats to prevent rheumatic fever.
Working alongside the Healthy Skin & ARF Prevention team, clinicians and other researchers; Elder researchers and community members have driven the co-design of healthy skin promotion resources localised to their community.
Designed by community for community, the Strong Skin App is a go-to resource to support your skin health.
The impact of mitral regurgitation from pediatric rheumatic heart disease and its effect on left ventricular remodeling and function following surgical intervention is uncertain. The objective is to explore the impact of mitral valve surgeries on myocardial mechanics, remodeling and function and identify pre-operative predictors of post-operative dysfunction which may contribute to the optimal timing of intervention.
For decades, the research community has called for participant information sheets/consent forms (PICFs) to be improved. Recommendations include simplifying content, reducing length, presenting information in layers and using multimedia. However, there are relatively few studies that have evaluated health consumers' (patients/carers) perspectives on the type and organisation of information, and the level of detail to be included in a PICF to optimise an informed decision to enter a trial.
SARS-CoV-2 infection is associated with a significant risk of hospitalisation, death, and prolonged impact on quality of life. Evaluation of new treatment options and optimising therapeutic management of people hospitalised with SARS-CoV-2 infection remains essential, but rapid changes in pandemic conditions and potential therapies have limited the utility of traditional approaches to randomised controlled trials.